重要提醒:2025.12.15 12:00-12:50期间发布的求助,下载出现了问题,现在已经修复完毕,请重新下载即可。如非文件错误,请不要进行驳回。

Vascular Resection for Pancreas Cancer – 10-year Experience from a Single High Volume-center

医学 胰十二指肠切除术 围手术期 胰腺切除术 腺癌 单中心 旁侵犯 胰腺 病态的 内科学 胰腺导管腺癌 回顾性队列研究 胃肠病学 胰腺癌 外科 癌症
作者
David Henault,Holden Kunde,Cody Zatzman,Daniela Bevacqua,Danielle Arshinoff,Sean P. Cleary,Laura A. Dawson,Elena Elimova,Robert C. Grant,Ali Hosni,Raymond Jang,Jennifer J. Knox,Aruz Mesci,Malcolm Moore,Carol‐Anne Moulton,Trevor Reichman,Chaya Shwaartz,Erica S. Tsang,Ian D. McGilvray,Steven Gallinger
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
被引量:2
标识
DOI:10.1097/sla.0000000000006567
摘要

Objective & Background: Combined pancreatic and vascular resections are increasingly performed for pancreatic ductal adenocarcinoma (PDAC). We evaluated the outcomes after pancreatectomy with non-vascular resection (NVR), venous resection (VR), and arterial resection (AR). Methods: Retrospective review (2011–2023) of 715 PDAC patients treated with curative-intent surgery. Associations among clinicopathological data, perioperative therapy, time to recurrence (TTR), and overall survival (OS) were evaluated. Results: Initial staging revealed 533 resectable, 98 borderline, and 84 locally advanced PDAC cases. Pancreaticoduodenectomy was the most common procedure (n=467). NVR was performed in 351 (58.2%) patients, VR in 181 (30.0%), and AR in 70 (11.8%). The median TTR and OS did not significantly differ according to the initial staging or type of pancreas resection. Median TTR and OS were significantly shorter for VR (14.5 and 22.7 mo) compared to NVR (18.6 and 30.5 mo, P <0.001) and AR (20.6 and 30.9 mo, P =0.004 and P =0.017). Chemotherapy or chemoradiation significantly prolonged TTR (20.1 vs. 10.2 mo, P <0.001 and 25.3 vs. 16.4 mo, P <0.001) and OS (31.5 vs. 17.2 mo, P <0.001 and 35.5 vs. 27.5 mo, P =0.030). AR was associated with higher 90-day mortality rates. In the multivariable analysis, vascular resection was not associated with OS. Perioperative therapy, pathological N0 status, and absence of perineural invasion were the key predictors of longer TTR and OS. Conclusions: Pancreatectomy with AR was not associated with worse oncological outcomes when controlling for perioperative therapy. However, AR was associated with higher 90-day mortality rates. Patient selection is crucial when performing AR in patients with PDAC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彩色的诗桃完成签到,获得积分10
刚刚
1秒前
chanlei发布了新的文献求助10
1秒前
浮游应助体贴的小天鹅采纳,获得10
2秒前
orixero应助小鲸鱼很可爱采纳,获得10
2秒前
朱大帅发布了新的文献求助10
2秒前
lql完成签到 ,获得积分10
3秒前
3秒前
大个应助guangshuang采纳,获得10
3秒前
梓墨发布了新的文献求助10
4秒前
4秒前
Rabbit完成签到 ,获得积分10
5秒前
KYT完成签到,获得积分10
5秒前
河句完成签到 ,获得积分10
6秒前
7秒前
葛一豪发布了新的文献求助30
7秒前
晓婷婷完成签到,获得积分10
7秒前
MMMM完成签到 ,获得积分10
8秒前
KYT发布了新的文献求助10
8秒前
彭于晏应助ddd采纳,获得30
9秒前
chanlei完成签到,获得积分20
9秒前
9秒前
太阳罗山的地方完成签到,获得积分10
10秒前
浮游应助科研通管家采纳,获得10
10秒前
111完成签到,获得积分10
10秒前
上官若男应助科研通管家采纳,获得10
10秒前
10秒前
华仔应助科研通管家采纳,获得10
10秒前
Jasper应助科研通管家采纳,获得10
10秒前
SciGPT应助科研通管家采纳,获得10
10秒前
且慢应助科研通管家采纳,获得10
10秒前
小明应助科研通管家采纳,获得20
10秒前
完美世界应助科研通管家采纳,获得10
10秒前
CodeCraft应助科研通管家采纳,获得100
10秒前
10秒前
浮游应助科研通管家采纳,获得10
10秒前
小二郎应助科研通管家采纳,获得10
10秒前
量子星尘发布了新的文献求助10
10秒前
浮游应助科研通管家采纳,获得10
10秒前
领导范儿应助科研通管家采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
List of 1,091 Public Pension Profiles by Region 1001
Latent Class and Latent Transition Analysis: With Applications in the Social, Behavioral, and Health Sciences 500
On the application of advanced modeling tools to the SLB analysis in NuScale. Part I: TRACE/PARCS, TRACE/PANTHER and ATHLET/DYN3D 500
L-Arginine Encapsulated Mesoporous MCM-41 Nanoparticles: A Study on In Vitro Release as Well as Kinetics 500
Haematolymphoid Tumours (Part A and Part B, WHO Classification of Tumours, 5th Edition, Volume 11) 400
Virus-like particles empower RNAi for effective control of a Coleopteran pest 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5467931
求助须知:如何正确求助?哪些是违规求助? 4571421
关于积分的说明 14330283
捐赠科研通 4497999
什么是DOI,文献DOI怎么找? 2464266
邀请新用户注册赠送积分活动 1453006
关于科研通互助平台的介绍 1427707